atai Life Sciences (ATAI) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ATAI · Stock Price

USD 4.01+2.62 (+188.49%)

Market Cap: $1.5B

Historical price data

Market Cap: $1.5BPatents: 2Founded: 2025HQ: Berlin, Germany

Sector Ranking#22 in Neuroscience & CNS

Overview

AtaiBeckley, formed from the strategic combination of atai Life Sciences and Beckley Psytech, is a global biotech leader focused on transforming mental healthcare through novel psychedelic-derived therapeutics. Its core strategy employs a decentralized platform to identify, incubate, and fund subsidiary programs, de-risking development across a diversified pipeline. Key near-term catalysts include Phase 2 readouts for its lead programs—BPL-003 and VLS-01 in treatment-resistant depression and EMP-01 in social anxiety disorder—positioning it at the forefront of a potentially paradigm-shifting treatment modality.

DepressionSocial Anxiety Disorder

Technology Platform

A decentralized biotech platform providing subsidiary programs with integrated expertise in regulatory strategy, clinical trial design for Schedule I compounds, data science, and formulation/delivery innovation for psychedelic-based neuroplastogens.

Funding History

5

Total raised:$579.2M

IPO$211.2MUndisclosedJun 18, 2021

PIPE$175MUndisclosedJun 15, 2021

Series C$125MUndisclosedMar 15, 2021

Series B$43MPeter ThielMar 15, 2020

Opportunities

The company is targeting a massive, underserved market in mental health, particularly treatment-resistant depression, with the potential for rapid-acting, durable therapies that could command premium pricing.

Near-term clinical catalysts in 2025-2026 for its Phase 2 programs provide clear inflection points for value creation.

Risk Factors

High clinical and regulatory risk associated with novel psychedelic compounds; future capital needs for Phase 3 trials may lead to shareholder dilution; and significant commercialization challenges around payer reimbursement, clinician training, and patient adoption of the interventional psychiatry model.

Competitive Landscape

Competes directly with other public psychedelic biotechs like COMPASS Pathways in TRD, and faces potential future competition from large pharmaceutical companies entering the neuroplastogen space. Its platform model and focus on optimized formulations are key differentiators.